**Table, Supplemental Digital Content 3.** Significant differencesin prognostic scoresbetween the countries and the global cohort (country vs, global cohort).

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Spain**  **n=84** | **Mexico**  **n=222** | **Korea**  **n=274** | **USA**  **n=291** | **Colombia**  **n=40** | **France**  **n=66** | **Brazil**  **n=90** | **India**  **n=366** | **Chile**  **n=28** | **UK**  **n=1,092** | **Canada**  **n=28** |
| **MELD** |  | 30.9 vs, 23.1\* | 20.3 vs,  23.7\* | 24.7 vs,  23.4# |  |  | 26.5 vs,  23.4# | 22.6 vs,  23.6# | 21.2 vs,  23.5# |  |  |
| **MELD-Na** | 21.2 vs,  26.9\* | 32.7 vs,  26.2\* | 23.5 vs,  27.1\* | 28.4 vs,  26.5\* |  |  | 30.7 vs,  26.6# |  |  | 26.3 vs,  27.6# |  |
| **mDF** |  | 71.6 vs,  54.6\* | 38 vs,  57.5\* |  |  |  |  | 66.1 vs,  54.4\* | 40.9 vs,  55.8# |  |  |
| **GAHS** | 9 vs, 9\* | 10 vs, 8\* | 8 vs, 9\* |  | 9 vs, 9# |  | 9 vs, 9# |  |  | 8 vs, 9\* |  |
| **ABIC** |  | 8.5 vs, 7.9\* | 7.5 vs, 8# |  | 8.8 vs, 7.9# |  |  | 7.5 vs, 8\* |  |  |  |

#p<0.05 \*p<0.001

MELD: model for end-stage liver disease, mDF: Maddrey’s discriminant function, GAHS: Glasgow alcoholic hepatitis score, ABIC: age, bilirubin, international normalized ratio and creatinine score